« Back
A multianalyte algorithm PCR-based blood test outperforms single analyte ELISA-based blood tests for neuroendocrine tumor detection
Poster Title: A multianalyte algorithm PCR-based blood test outperforms single analyte ELISA-based blood tests for neuroendocrine tumor detection
Submitted on 26 Mar 2014
Author(s): Mark Kidd, Irvin M Modlin, Daniele Alaimo, Stephen Callahan, Nancy Teixiera, Lisa Bodei, Ignat Drozdov
Affiliations: Wren Laboratories, 35 NE Industrial Road, Branford CT 06405
Poster Views: 2,729
View poster »

Poster Information
Abstract: A key issue in management of neuroendocrine tumors (NETs) is specific and sensitive biomarkers. Measurements of single analytes in blood are widely utilized but have significant limitations. We developed a 51 transcript blood NET signature and compared it with standard approaches.
Methods: The multigene signature was evaluated in prospectively collected NETs (n=41, 61% small intestinal, 50% metastatic, 44% under treatment). These were age (NETs: mean 56.9 years, range: 31-76; controls: mean 56.4, range: 33-75) and sex-matched (M:F 10:31) with controls (1:1). Samples were analyzed by 2-step PCR protocol and ELISAs: (DAKO-CgA), pancreastatin (CusaBio-PST) and neurokinin A (RayBiotech-NKA). Sensitivity comparisons included chi-square, non-parametric measurements and ROC analyses.
Results: The NETest identified thirty eight of 41 NETs with equivalent performance metrics: sensitivity/specificity 93% and an AUC of 0.96. For the single analyte ELISA assays, metrics ranged from 31-93% and AUCs from 0.55-0.67. The multigene transcript NETest significantly outperformed single analyte tests (Z-statistic=4.85-6.58, p<0.0001).
Conclusions: A 51 panel multigene blood transcript analysis is significantly more sensitive and efficient (>93%) than any single analyte assay (CgA, PST or NKA) for NET detection. Our data indicate that a blood-based multigene analytic measurement will provide increased sensitivity and specificity in minimally invasive disease detection.
Summary: In a prospective study, in age-/sex- and ethnicity-matched patients and controls (n=82), a 51 panel multigene blood transcript test (NETest) was identified to be significantly more sensitive and accurate (>93%) than any single analyte assay (Chromogranin A, Pancreastatin or Neurokinin A) for neuroendocrine tumor detection. References: 1. Modlin IM, Drozdov I, Kidd M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PlosOne 2013; e63364
2. Modlin I, Drozdov I, Kidd M: Gut neuroendocrine tumor blood qpcr fingerprint assay: Characteristics and reproducibility. Clinical Chemistry 2014;52:419-429.
3. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
4. Kanakis G, Kaltsas G: Biochemical markers for g
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Genetic Engineering in Male Sterility for Hybrid Variety Development
Abir Hasan Joy

Helana Lutfi and Shaban Nuredini

Machine Learning: A New Breakthrough in Medical Diagnosis
Punitha Mahendran, Anis Joelaira, Chai Yong Chia, Fazidatul Aziz, Hasyimah Emran, Siew Fun Lee, Wai Kit Wong, Yee Yan Tang, Li Yang Wong

BAT Molecular Imaging with SPECT-CT, PET-CT, PET-MRI and Fluorescence-PET: A Systematic Review of the Literature Data
Tarik Z Belhocine, MD., Ph.D *, Albert A Driedger, MD., Ph.D **, Jean-Luc Urbain, MD., Ph.D ***

Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon